Why Are Prolactinomas Larger at Diagnosis in Men? Explained

Men who develop a prolactinoma—a usually noncancerous tumor of the pituitary gland at the base of the brain—are often diagnosed with significantly larger tumors (macroadenomas) than women. The primary reason for this is a delay in diagnosis: the early symptoms of high prolactin in men are gradual and easily mistaken for everyday stress or aging, whereas in women, the symptoms are often more immediate and noticeable ^[1][2]. As a result, the tumor frequently has months or years to grow undetected until it causes noticeable physical symptoms ^[3][4].

Below is a breakdown of why this diagnostic gap occurs, what it means for your treatment, and how tumor biology might also play a role.

The Symptom Difference: Gradual vs. Obvious

Prolactinomas cause hyperprolactinemia (high levels of prolactin in the blood), which suppresses the body’s sex hormones ^[2]. The way this hormone drop is experienced depends heavily on biological sex:

• In people who menstruate: High prolactin often disrupts the menstrual cycle, leading to missed periods (amenorrhea), infertility, or unexpected breast milk production (galactorrhea) ^[1]. These sudden, clear changes usually prompt early blood tests, catching the tumor when it is still very small.
• In men: High prolactin suppresses testosterone production ^[2]. The symptoms of low testosterone are gradual and include decreased sex drive (libido), erectile dysfunction, fatigue, and mood changes ^[1].

Because sexual dysfunction and fatigue develop slowly, they are often attributed to normal aging or stress, and men may be hesitant to report them ^[1][5]. As a result, the hormonal imbalance can go undetected for a very long time. For example, one retrospective study used a drop in hemoglobin as an indirect proxy for low testosterone and estimated that the men in their cohort had experienced untreated hypogonadism for an average of 6.1 years before their prolactinoma was finally diagnosed ^[5].

Discovery Through Compression

Because early hormonal clues are often missed, a man’s prolactinoma is frequently only discovered once it has grown larger than 1 centimeter (a macroadenoma) and begins to press on surrounding structures at the base of the brain ^[3].

When a tumor reaches this size, it can cause physical symptoms, such as:

• Vision changes: The pituitary gland sits directly below the optic chiasm (where the optic nerves cross). A large tumor can press upward into these nerves, often causing a loss of peripheral vision ^[3].
• Headaches: Large tumors are associated with headaches, though the exact cause is not always clear ^[4].
• Hypopituitarism: A large tumor can compress the normal pituitary gland, impairing its ability to produce other essential hormones ^[3]. This can result in reduced ACTH (which signals the adrenal glands to make cortisol) and reduced TSH (which signals the thyroid).

Urgent Warning: Seek emergency medical care if you experience a sudden, severe headache, sudden or rapidly worsening vision or double vision, vomiting, confusion, fainting, or marked weakness. These can be signs of pituitary apoplexy (bleeding into the tumor) or severe adrenal insufficiency (critically low cortisol) and require immediate medical assessment.

What This Means for Your Treatment

Finding out you have a large tumor at the base of the brain can be frightening, but a large prolactinoma does not automatically mean you need surgery or have a poor outlook. The first-line treatment for most prolactinomas—even large macroadenomas—is medication called a dopamine agonist (such as cabergoline). These medications are often highly effective at lowering prolactin levels and shrinking the tumor, which can relieve pressure on your optic nerves and improve symptoms. Surgery or other treatments are generally reserved for cases where medication is ineffective, not tolerated, or if vision requires urgent intervention.

Does Biology Matter?

While a delayed diagnosis is a major factor, researchers are exploring whether male prolactinomas are also biologically distinct. Some studies suggest that even when men and women have reported symptoms for a similar length of time, men still tend to have larger tumors ^[6].

Biological research suggests that male prolactinomas may have lower levels of estrogen-receptor-alpha (ERα) and differences in androgen-receptor (AR) signaling ^[7][8]. These are proposed associations that might be linked to tumor size or how the tumor responds to medication. However, these are population-level findings—they do not predict any individual patient’s outcome. Your response to treatment will be determined by your specific blood tests and MRI results, not just your sex or the initial size of the tumor.